menu
    • menu
    [{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AGMB-129","moa":"ALK-5 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ Undisclosed"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AGMB-129","moa":"ALK-5 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AgomAb Therapeutics N.V \/ Undisclosed"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AGMB-129","moa":"ALK-5 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AgomAb Therapeutics N.V \/ Undisclosed"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AGMB-129","moa":"ALK-5 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ Undisclosed"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Series C Financing","leadProduct":"AGMB-129","moa":"ALK-5 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ EQT Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ EQT Life Sciences"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2024","type":"Series D Financing","leadProduct":"AGMB-129","moa":"ALK-5 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ Sanofi"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BELGIUM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AGMB-129","moa":"ALK-5 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ Undisclosed"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AGMB-129","moa":"ALK-5 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ Undisclosed"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Series B Financing","leadProduct":"AGMB-129","moa":"ALK-5 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0.11,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.11,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ Pfizer Inc"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AGMB-129","moa":"ALK-5 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgomAb Therapeutics N.V \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ Undisclosed"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2021","type":"Series B Financing","leadProduct":"AGMB-101","moa":"MET receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"AgomAb Therapeutics N.V","amount2":0.070000000000000007,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"AgomAb Therapeutics N.V \/ Redmile Group","highestDevelopmentStatusID":"5","companyTruncated":"AgomAb Therapeutics N.V \/ Redmile Group"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Origo Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"ORG-129","moa":"TGF-beta","graph1":"Immunology","graph2":"Phase I","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ AgomAb Therapeutics N.V","highestDevelopmentStatusID":"6","companyTruncated":"AgomAb Therapeutics N.V \/ AgomAb Therapeutics N.V"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AGMB-447","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AgomAb Therapeutics N.V \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AgomAb Therapeutics N.V \/ Undisclosed"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"BELGIUM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AGMB-447","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AgomAb Therapeutics N.V \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AgomAb Therapeutics N.V \/ Undisclosed"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AGMB-447","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AgomAb Therapeutics N.V \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AgomAb Therapeutics N.V \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by AgomAb Therapeutics N.V

    Menu

    AgomAb Therapeutics N.V

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            AllPack Indonesia
                            Not Confirmed

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AGMB-129

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Multiple Ascending Dose Study with AGMB-129 in Healthy Participants

                            Details : AGMB-129 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Crohn Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 12, 2025

                            Lead Product(s) : AGMB-129

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            AllPack Indonesia
                            Not Confirmed

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AGMB-129

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Agomab Reports Positive Phase 2a Results for AGMB-129 in Crohn’s Disease

                            Details : AGMB-129 is an oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (TGF-β RI or ALK5), being studied for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 10, 2025

                            Lead Product(s) : AGMB-129

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            AllPack Indonesia
                            Not Confirmed

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AGMB-129

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Sanofi

                            Deal Size : $89.0 million

                            Deal Type : Series D Financing

                            DEALS_DEV arrow-down

                            Agomab Announces $89 Million Series D Financing to Support Broad Fibrosis-Focused Pipeline

                            Details : The proceeds from the financing will be used to further advance the ongoing clinical development of Agomab’s lead candidate, AGMB-129 in patients with fibrostenosing Crohn’s disease (FSCD).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 25, 2024

                            Lead Product(s) : AGMB-129

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Sanofi

                            Deal Size : $89.0 million

                            Deal Type : Series D Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            AllPack Indonesia
                            Not Confirmed

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AGMB-447

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Agomab Receives FDA Orphan Drug Designation for AGMB-447 in Idiopathic Pulmonary Fibrosis

                            Details : AGMB-447 is an inhaled lung-restricted small molecule inhibitor of ALK5 (TGFβRI or ALK5). It is under clinical development for the treatment of patients with idiopathic pulmonary fibrosis (IPF).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 06, 2024

                            Lead Product(s) : AGMB-447

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            AllPack Indonesia
                            Not Confirmed

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AGMB-129

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Relative Bioavailability and Effect of Food Study With AGMB-129 in Healthy Participants

                            Details : AGMB-129 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 03, 2024

                            Lead Product(s) : AGMB-129

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            AllPack Indonesia
                            Not Confirmed

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AGMB-447

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants W...

                            Details : AGMB-447 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 26, 2023

                            Lead Product(s) : AGMB-447

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            AllPack Indonesia
                            Not Confirmed

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AGMB-447

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Agomab Starts Phase 1 Clinical Study for AGMB-447 in Healthy Subjects and Patients with Idiopathic Pulmonary F...

                            Details : AGMB-447 is an inhaled lung-restricted small molecule inhibitor of ALK5 (TGFβRI or ALK5). It is under phase 1 clinical development for the treatment of patients with idiopathic pulmonary fibrosis (IPF).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 14, 2023

                            Lead Product(s) : AGMB-447

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            AllPack Indonesia
                            Not Confirmed

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AGMB-129

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : EQT Life Sciences

                            Deal Size : $100.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline

                            Details : Proceeds will support Phase 2 candidate AGMB-129/ORG-129 for Fibrostenosing Crohn’s Disease and development of a highly innovative pipeline of anti-fibrotic and regenerative therapies, including AGMB-447 for idiopathic pulmonary fibrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 11, 2023

                            Lead Product(s) : AGMB-129

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : EQT Life Sciences

                            Deal Size : $100.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            AllPack Indonesia
                            Not Confirmed

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AGMB-129

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Agomab Receives FDA Fast Track Designation for AGMB-129 in Fibrostenosing Crohn’s Disease and Starts STENOVA...

                            Details : AGMB-129 (ORG-129) is an oral, small molecule GI-restricted inhibitor of ALK-5 (or TGFbR1) for the treatment of Fibrostenosing Crohn’s Disease. TGFb is a known master regulator of fibrosis and preliminary clinical data supports targeting the pathway in...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 05, 2023

                            Lead Product(s) : AGMB-129

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            AllPack Indonesia
                            Not Confirmed

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AGMB-129

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Drug-Drug Interaction Study With AGMB-129 and Midazolam in Healthy Participants

                            Details : AGMB-129 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 10, 2023

                            Lead Product(s) : AGMB-129

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth